Exarafenib

DB17582InvestigationalSmall molecule

Exarafenib: Overview.

Mechanism: Pharmacologically active on RAF proto-oncogene serine/threonine-protein kinase, Serine/threonine-protein kinase A-Raf, and Serine/threonine-protein kinase B-raf
Curator reviewed
Formula / weight: C₂₆H₃₄F₃N₅O₃ · 521.585 g/mol (avg)
Also known as: KIN-2787 free base

Resolves to

Compound

Structure

InChIKeyGZMYLSJUNSCMTD-MOPGFXCFSA-NSMILESC[C@H](CO)NC1=CC(=CC(=N1)N1CCOCC1)C1=CC(NC(=O)N2CC[C@@H](CC(F)(F)F)C2)=CC=C1C

Targets

What you can answer from here — as of September 23, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

7+ReferencesStructured and connected to the statements they support

Which drugs share a target with Exarafenib, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.